

# MEDICAL POLICY UPDATE

August 2022



## IN THIS ISSUE

|  |   |
|--|---|
| Coverage Guidelines Revised for Omalizumab (Xolair) .....                                  | 4 |
| Criteria Established for Dexamethasone Punctum Insert (Dextenza).....                      | 4 |
| Criteria revised for Medical Policy M-13, Intraoperative Neurophysiologic Monitoring ..... | 5 |
| Obstructive Sleep Apnea Publication Delayed.....   | 5 |



Policy

| <b>Policy Title</b>                                    | <b>Anticipated Issue Date</b> | <b>30 Day Notification Information</b>   |
|--|-------------------------------|--|
| E-5 Tumor Treatment Fields                             | 10/03/2022                    | This policy is up for annual review. There are no indications for a change in coverage at this time. Policy will publish on October 3, 2022.                                       |
| G-46 Inhaled Nitric Oxide                              | 10/10/2022                    | This policy is up for annual review. Minor administrative updates made. Policy will publish on October 10, 2022.   |
| G-9 Diagnosis and Treatment of Male Sexual Dysfunction | 10/10/2022                    | This policy is up for annual review. There are no indications for a change in coverage at this time. Policy will publish on October 10, 2022.                                      |
| I-199 Tildrakizumab-asmn (Ilumya)                      | 08/29/2022                    | This policy is being updated to include new to market Skyrizi IV formulation. Policy will publish August 29, 2022.   |
| I-213 Brexanolone (Zulresso)                           | 10/03/2022                    | This policy is up for annual review. A Medical Policy Update (MPU) newsletter is not required; the policy will publish on October 3, 2022 with the standard 30 day notification.   |
| I-28 Infliximab and Infliximab Biosimilars             | 10/24/2022                    | This policy is up for annual review. A Medical Policy Update (MPU) newsletter is not required; the policy will publish on October 24, 2022.  |
| I-37 Ustekinumab (Stelara)                             | 10/10/2022                    | This policy is up for annual review. A Medical Policy Update (MPU) newsletter is not required; the policy will publish on October 10, 2022.  |
| I-53 Omalizumab (Xolair)                               | 10/24/2022                    | This policy is up for annual review. A Medical Policy Update (MPU) newsletter is not required; the policy will publish on October 24, 2022 with a 90 day notification.             |
| I-78 Intravitreal Implants                             | 11/28/2022                    | This policy is up for annual review. A Medical Policy Update (MPU) newsletter is not required; the policy will publish on November 28, 2022 with a 90 day notification.            |
| I-88 Granulocyte Colony-Stimulating Factors            | 11/01/2022                    | This policy is being updated to include new to market therapy pegfilgrastim-pbbk Fylnetra biosimilar to Neulasta. Policy will publish November 1, 2022.                            |
| L-10 Selected Tests for Rheumatic Diseases             | 10/10/2022                    | This policy is scheduled for annual review. Procedural and Diagnosis coding updated, otherwise minor administrative changes. This policy is scheduled to publish October 10, 2022. |
| L-191 Intracellular Micronutrient Testing Panel        | 10/10/2022                    | This policy is up for annual review. Minor administrative updates made. Policy will publish on October 10, 2022.   |

| Policy Title   | Anticipated Issue Date | 30 Day Notification Information  |
|--|------------------------|--|
| L-260 Prostate Specific Antigen  | 10/10/2022             | This policy is up for annual review. Minor administrative updates made. Policy will publish on October 10, 2022  |
| M-13 Intraoperative Neurophysiologic Monitoring (Sensory-Evoked Potentials, Motor-Evoked Potentials, EEG Monitoring) | 11/28/2022             | This policy was reviewed on a request from FIPR. Additional criteria include documentation of American Board of Medical Specialties certification and the monitoring of one case at a time. An MPU is necessary, and the policy will publish on November 28, 2022. |
| M-7 Electronystagmography and Videonystagmography Services   | 10/03/2022             | Maintain the current POS listed in the policy as inpatient/outpatient with the default statement. Policy will publish on October 3, 2022.  |
| S-201 Balloon Ostial Dilation of the Sinus and Implantable Sinus Stents  | 10/10/2022             | This policy is scheduled for annual review. Minor administrative updates made. Policy is scheduled to publish October 10, 2022.  |
| V-2 Concurrent Care  | 10/03/2022             | This policy is a benefit policy. There is no indication to revise the criteria. Policy will publish on October 3, 2022.  |
| V-3 Billing of Observation Services  | 10/03/2022             | This policy is up for annual review. The coding is being revised and updated to only include applicable procedure codes of observation services. Policy will publish on October 3, 2022.   |
| Y-12 Urinary Incontinence Treatment  | 10/17/2022             | This policy is scheduled for annual review. There was an addition to the criteria for coverage of artificial urinary sphincter. An MPU is not required, and the policy will publish on October 17, 2022.   |
| Z-1 Ultraviolet Light Therapies  | 10/17/2022             | This policy is up for annual review. There was an addition of coverage for additional conditions. An MPU is not necessary, and the policy will publish on October 17, 2022.  |
| Z-38 Hospital Admission Provision (Benefits After Contract Termination)  | 10/03/2022             | This policy is a benefit policy. Maintain the current POS listed in the policy as inpatient with the default statement. Policy will publish on October 3, 2022.  |



## Coverage Guidelines Revised for Omalizumab (Xolair)



Highmark Blue Shield of Northeastern New York has revised criteria for omalizumab (Xolair) subcutaneous injection to add reauthorization criteria along with the initial and reauthorization periods. The reauthorization criteria include that the individual meets all initial authorization criteria and has demonstrated disease stability or a beneficial response to therapy.

This revised Medical Policy will apply to professional providers and facility claims. The effective date is November 28, 2022

**Place of Service: Outpatient**

Please refer to Medical Policy I-53, Omalizumab (Xolair), for additional information.

## Criteria Established for Dexamethasone Punctum Insert (Dextenza)



Highmark Blue Shield of Northeastern New York has established new guidelines for dexamethasone punctum insert (Dextenza). Dexamethasone punctum insert (Dextenza) may be considered medically necessary for individuals 18 years of age or older for the treatment of **ANY ONE** of the following criteria:

- Ocular inflammation and pain following ophthalmic surgery; **or**
- Ocular itching associated with allergic conjunctivitis after treatment failure with all of the following unless contraindicated:
  - Topical ophthalmic antihistamines; **and**
  - Topical ophthalmic mast cell stabilizers; **and**
  - Topical ophthalmic corticosteroids.

This revised Medical Policy will apply to professional providers and facility claims. The effective date is October 17, 2022.

**Place of Service: Outpatient**

Please refer to Medical Policy I-78, Intravitreal Implants, for additional information.

---

## Criteria revised for Medical Policy M-13, Intraoperative Neurophysiologic Monitoring



Highmark Blue Shield of Northeastern New York has revised criteria for Medical Policy M-13, Intraoperative Neurophysiologic Monitoring (Sensory-Evoked Potentials, EEG Monitoring).

Intraoperative Neurophysiologic Monitoring may be considered medically necessary when performed by an operator who is certified by the American Board of Medical Specialties (ABMS); **and**

Monitoring only one (1) procedure at a time.

This revised Medical Policy will apply to professional providers and facility claims. The effective date is 11/28/2022.

### **Place of Service: Inpatient/Outpatient**

Please refer to Medical Policy M-13, Intraoperative Neurophysiologic Monitoring (Sensory-Evoked Potentials, EEG Monitoring) for additional information.

---

## Obstructive Sleep Apnea Publication Delayed



In May 2022, Highmark Blue Shield of Northeastern New York announced revised coverage guidelines for Diagnosis and Treatment of Obstructive Sleep Apnea in Adult and Pediatric Individuals effective August 29, 2022.

Highmark Blue Cross Blue Shield is delaying the publication of Diagnosis and Treatment of Obstructive Sleep Apnea in Adult and Pediatric Individuals in addition to delaying the archiving of HMK M-62, Polysomnography for Non-Respiratory Sleep Disorders. The revised policy publication effective date is September 26, 2022.

Please refer to Medical Policies Z-8 Diagnosis and Treatment of Obstructive Sleep Apnea in Adults, Z-64 Diagnosis and Treatment of Obstructive Sleep Apnea in Pediatric individuals, and M-62 Polysomnography for Non-Respiratory Sleep Disorders, for additional information.

### **Place of Service: Inpatient/Outpatient**



## Comments on These Medical Policies?

We want to know what you think about our new medical policy changes. Send us an email with any questions or comments that you may have on the new medical policies in this edition of Medical Policy Update.

Write to us at [medicalpolicy@highmark.com](mailto:medicalpolicy@highmark.com)



[eSubscribe](#)



## About this Newsletter

*Medical Policy Update* is a monthly newsletter for the health care providers who participate in our networks and submit claims to Highmark using the appropriate HIPAA transactions or claim forms as required by Highmark. This publication focuses only on medical policy and claims administration updates, including coding guidelines and procedure code revisions, and is the sole source for this information. For all other news, information and updates, be sure to read [Provider News](#), available on the Provider Resource Center at [hnenybs.highmarkprc.com](http://hnenybs.highmarkprc.com).

Highmark Blue Shield of Northeastern New York is a trade name of Highmark Western and Northeastern New York Inc., an independent licensee of the Blue Cross Blue Shield Association. NaviNet is a registered trademark of NaviNet, Inc., which is an independent company that provides a secure, web-based portal between providers and health care insurance companies.

*Note: This publication may contain certain administrative requirements, policies, procedures, or other similar requirements of Highmark Blue Shield of Northeastern New York (or changes thereto) as well as interpretations of certain administrative requirements, policies, and procedures (hereinafter collectively "requirements") which are binding upon Highmark BSNENY contracted providers. Therefore, the requirements in this publication supplement the Provider Manual. Pursuant to their contract with Highmark BSNENY, Highmark BSNENY contracted providers must comply with any requirements included herein, as part of the Program Requirements under such contract, unless and until such item(s) are subsequently modified in whole or in part, except that for so long as Highmark BSNENY members remain on the "Legacy System" (not yet moved to Highmark's system), certain legacy medical protocols (found at [bsneny.com](http://bsneny.com)) shall apply and control until the earlier of such time as such member is no longer on the Legacy System or Highmark BSNENY communicates otherwise to you.*